deal sight focu intern
messag report financi exceed estim earn per
share revenu slightli lower expect howev guidanc full
year remain perhap one import question receiv
investor regard busi develop provid opinion potenti
deal manag commentari note
sinc engag three mega-merg includ warner lambert
pharmacia wyeth mani investor speak want understand
next mega-target might also rememb fail
attempt acquir astrazeneca azn allergan
respect contrast ceo ian read investor call morn attempt
dissuad thought say compani invest pipelin pfizer
state call continu evalu strateg situat believ beyond
lyrica expiri june abl grow revenu beyond mid
high singl digit earn per share even higher mean
mega-merg marker know typic side histori believ
tend repeat
claim late-stag pipelin suffici counter headwind loe includ
lyrica would agre pfe pipelin impress stand-alon competit
taken account pipelin valu might enough off-set loss
loe believ xtandi may offer short- medium-term growth opportun
prostat cancer stress competit come johnson johnson although
differenti pneumococc vaccin merck anticip launch
vaccin may fall time frame furthermor believ bavencio
abl catch keytruda opdivo io space stay oncolog
acknowledg ibranc pole posit inhibitor point lilli
novarti nv may take market share although class whole expect
grow product favor talazoparib lorlatinib tafamidi could also bring
revenu futur howev question enough
gener growth believ unlik suggest us larg merger still
updat estim base perform guidanc
manag commentari today earn call ep estim remain
revenu continu model loe lyrica follow market
entri gener begin dilut share count reflect
share repurchas program anticip occur per compani
estim effect tax rate remain addit made slight
chang oper gross margin beyond base manag
commentari made call manag expect margin remain roughli
outer year
valuat risk
valuat valuat assum unchang termin growth rate
wacc revenu model assum gener competit includ pfe
valuabl pipelin asset perspect predominantli ph risk-adjust
basi maintain neutral rate
page analyst certif import disclosur
downsid risk risk rate estim valuat includ higher-than
anticip oper expens new product launch perform wors
expect lead lower profit pipelin setback may alter futur revenu
assumpt push back launch date increas competit gip voc
landscap particularli oncolog may slow initi demand new product
price new brand product
upsid risk risk upsid includ favor clinic data readout new
product commerci regulatori legal chang favor product
page analyst certif import disclosur
million except per share number
good sold
amort intang asset
compani report guggenheim secur llc estim
page analyst certif import disclosur
